PCSK9 Antibody Alirocumab Attenuates Arterial Wall Inflammation Without Changes in Circulating Inflammatory Markers

To the Editor: Proprotein convertase subtilisin/kexin type 9 antibody (PCSK9ab) therapy reduces cardiovascular (CV) risk by lowering low-density lipoprotein cholesterol (LDL-C) levels, with a neutral effect on C-reactive protein (CRP) [(1)][1]. In view of the use of CRP as an inflammatory biomarker